Evaluation of How to Use Warfarin after Heart Valves Replacement Operations

Document Type : Original Article


1 Department of Cardiovascular Surgery, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

2 Department of anesthesiology, Faculty of medicine, Mashhad University of medical sciences, Mashhad, Iran

3 Faculty of medicine, Mashhad University of medical sciences, Mashhad, Iran

4 Department of Cardiovascular Surgery, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

5 Faculty Member of Parsmedicine Collge, Sabzevar University of Medical Sciences, Sabzevar, Iran.

6 Razavi Cancer Research Center, Razavi Hospital, Imam Reza International University, Mashhad, Iran.


Implantation of prosthetic valve requires a life time consumption of anticoagulation. Thrombotic and embolism complications as well as bleeding associated with anticoagulants are the leading cause of mortality and morbidity after heart valve surgery. Accordingly, this study is designed to explore and report the complications and factors related to usage of warfarin and constant check of prothrombin time and international normalized ratio.
This is an observational study in which the medical records of 100 patients with an average age of 47.9 ± 13.4 years undergoing surgery for replacement of heart valves were studied. All factors related to mortality and postoperative complications were extracted, and the patients were followed up for one year.
The results suggested that tricuspid valve insufficiency was significantly correlated other valvular defects.
Nine patients died; one patient in the operating room, one patient in the ICU, one patient in the ward and six patients during the first year died after the surgery. Two of the patients needed redo-surgery in the first year. It should be noted that among patients receiving warfarin on a regular basis (n=81), no mortality was reported in a one-year fallow-up.
In this study, out- of-hospital mortality only occurred in patients' irregular usage of warfarin and without follow-up coagulation tests.
So, we conclude that in developing country, if we cannot follow and train the patients constantly for warfarin usage and blood tests, mechanical valve utilization would be concomitant with high risk complications.


  1. Eugene B,  Fauci A.S, Fauci D.L, Hauser  S.L, Longo D.L, Jameson J. Harrison’s Principles of Internal Medicine.15 th Edition. McGrawHill. 2015.
  2. Shu Ch, Chen S, Qin T,  Fu Zh,  Sun T, Xie M, et al. Prevalence and correlates of valvular heart diseases in the elderly population in Hubei, China. Sci Rep. 2016; 6: 27253. DOI:10.1038/srep27253. PubMed PMCID:PMC4890003.
  3. Ozer N. Valvular heart disease epidemiology: a Turkish perspective. Arch Turk Soc Cardiol 2013; 41:11–13. doi: 10.5543/tkda.2013.91112.
  4. Wang Y.T,Tao J, Maimaiti A, Adi D, Yang Y.N, Yang Y.N, Li X.M, et al. Prevalence of valvular heart diseases and associated risk factors in Han, Uygur and Kazak population in Xinjiang, China. PLOS ONE  2017; 12(3): e0174490. DOI:10.1371/journal.pone.0174490. PubMed PMCID:PMC5371360.
  5. Nkomo V. T. et al. Burden of valvular heart diseases: a population-based study. Lancet 2006; 368: 1005–1011. DOI:10.1016/S0140-6736(06)69208-8.PubMed PMID:16980116.
  6.  Cheung D,  Duan B,  Butcher J.T. Current Progress in Tissue Engineering of Heart Valves: Multiscale Problems, Multiscale Solutions. Expert Opin Biol Ther. 2015; 15(8): 1155–1172. DOI:10.1517/14712598.2015.1051527. PubMed PMCID:PMC4883659
  7.  Choudhary Sh.K, Talwar S, Airan B. Choice of prosthetic heart valve in a developing country. Heart Asia. 2016; 8(1): 65–72. doi:  10.1136/heartasia-2015-010650. PubMed  PMID: 27326237.
  8.  Florath I, Albert A, Rosendahl U et al. Mid-term outcome and quality of life after aortic valve replacement in elderly people: mechanical versus stentless biological valves. Heart 2005; 91:1023–9. DOI:10.1136/hrt.2004.036178. PubMed: PMCID:PMC1769036
  9. Goldman L,  Schafer A.I. Goldman-Cecil Medicine. 25th edition. Elsiver. 2015.
  10. Brennan JM, Edwards FH, Zhao Y, et al. Long-term safety and effectiveness of mechanical versus biologic aortic valve prostheses in older patients: Results from the society of thoracic surgeons adult cardiac surgery national database. Circulation. 2013;127:1647-55. DOI:10.1161/CIRCULATIONAHA.113.002003. PubMed PMID: 23538379.
  11. Stassano P, Di Tommaso L, Monaco M, et al. Aortic valve replacement: A prospective randomized evaluation of mechanical versus biological valves in patients ages 55 to 70 years. J Am Coll Cardiol 2009;54:1862-8. DOI:10.1016/j.jacc.2009.07.032. PubMed: PMID:19892237.
  12. Menéndez-Jándula B, Souto JC, Oliver A, Montserrat I, Quintana M, Gich I, et al. Comparing Self-Management of Oral Anticoagulant Therapy with Clinic Management: a randomized trial. Annals of Internal Medicine. 2005;142: 1–10.PubMed PMID:15630104.
  13. Meijer KKim YKCarter DSchulman S. A prospective study of an aggressive warfarin dosing algorithm to reach and maintain INR 2 to 3 after heart valve surgery. Thromb Haemost. 2011 Feb;105(2):232-8. DOI:10.1160/TH10-05-0324. PubMed PMID:21173999.
  14. Kimmel SE, Chen Z, Price M, Parker CS, Metlay JP, Christie JD, et al. The influence of patient adherenceon anticoagulation control with warfarin: results from the International Normalized Ratio Adherence andGenetics (IN-RANGE) Study. Arch Intern Med 2007; 167(3): 229-35. DOI: 10.1001/archinte.167.3.229. PubMed PMID:17296877.
  15. Sawicki PT. A Structured Teaching and Self-management Program for Patients Receiving Oral Anticoagulation. JAMA  1999; 281(2): 145-50. PubMed PMID:9917117.